CD274 and melanoma: A recent study performed a systematic review and meta-analysis of the most relevant studies involving TIL therapy in advanced melanoma and reached several important conclusions: no difference was found in median OS between studies with prior anti-PD1 or anti-PDL1 treatment and without; ORR was 34% and 44% for the studies with and without prior anti-PD1 and anti-PDL1 treatment, respectively [123].